Compare Diamondback Energy Inc (FANG) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diamondback Energy Inc vs McKesson Corporation — how do they compare? Diamondback Energy Inc trades at $193 (market cap $53.67B), while McKesson Corporation trades at $936.09 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 2× Diamondback Energy Inc's market cap, and Diamondback Energy Inc pays the higher dividend (2.3%). Which is the better fit depends on your goals — on Pluang, investors hold Diamondback Energy Inc for 69 Days and McKesson Corporation for 74 Days on average.
| FANG | MCK | |
|---|---|---|
Market Cap | $53.67B | $108.46B |
Volume | 2,250,644 | 712,607 |
Sector | Energy | Health |
52-Week High | $213.69 | $995.69 |
52-Week Low | $137.29 | $725.17 |
Typical Hold Time | 69 Days | 74 Days |
Enterprise Value | $65.83B | $115.00B |
Dividend Yield | 2.3% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $184.38, down 0.32% on the day, with a bearish technical signal from moving averages. The company shows strong revenue growth from $14.93B in 2025 to projected $17.0B in 2026, though net margins have compressed. Recent Q2 2026 earnings beat expectations at $6.48 EPS versus $6.08 expected. Analyst sentiment remains overwhelmingly positive with 90.57% buy ratings and a $231.77 consensus price target, representing 26% upside from current levels.
FANG presents a compelling growth story with robust cash flow generation and strategic positioning in the Permian Basin. Key risks include oil price volatility and insider selling activity. The stock's current valuation at 36.51 P/E appears reasonable given growth prospects, while technical support at $182 provides a near-term floor. Institutional accumulation and strong analyst support suggest confidence in long-term value creation.
McKesson (MCK) trades at $910.33, down 1.23% over 24 hours, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue grew to $359.05 billion in 2025, though net margins remain thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing growth visibility in pharmaceutical distribution.
The outlook remains positive given analyst consensus favoring Buy ratings (80.65%) and a price target of $956.43, implying ~5% upside. Risks include margin pressure from drug pricing dynamics and policy uncertainty, while institutional accumulation and solid cash flow generation support stability. Earnings momentum and strategic partnerships position MCK for sustained growth, though investors should monitor competitive and regulatory headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
